Bukwang Pharm Joins Project to Develop Digital Therapeutic for Schizophrenia

MOU with Samsung Medical Center and Blue Signum
Collaborate on all aspects of Affectus development

Bukwang Pharm will participate in a project led by Samsung Medical Center and mental wellness startup Blue Signum to develop a digital therapeutic aimed at improving social cognition in people with schizophrenia.

Bukwang Pharm said on October 22 that it had signed an MOU with Samsung Medical Center and Blue Signum on the 15th to jointly develop Affectus, a software medical device.

Officials pose for a commemorative photo after signing an MOU on the 15th to jointly develop Affectus, a software medical device designed to improve social cognition in people with schizophrenia. From left: Lee Jeyoung, CEO of Bukwang Pharmaceutical; Choi Jeongseok, professor at Samsung Medical Center; and Yoon Junghyun, CEO of BlueSignum. Bukwang Pharmaceutical

Under the agreement, the three organizations will collaborate across all aspects of Affectus's development, including clinical development, product enhancement and regulatory approval, and clinical implementation and commercialization.

Through the agreement, Bukwang Pharm will combine its expertise in the central nervous system (CNS) field and experience commercializing pharmaceuticals with Samsung Medical Center's clinical research capabilities and Blue Signum's digital technology and product development capabilities. Building on their respective expertise, the organizations plan to work together to expand the clinical applicability of Affectus and develop it into a new treatment option in the future.

Affectus, a software medical device, is being developed to improve social cognition in people with schizophrenia. It is intended to support patients' daily lives and social reintegration through digital social cognition training. An exploratory clinical trial is currently underway at Samsung Medical Center.

Lee Jeyoung, CEO of Bukwang Pharm, said, "I am honored to take part in this meaningful project led by Samsung Medical Center. We will draw on Bukwang Pharm's expertise in the CNS field and work together to develop Affectus into a treatment option that can benefit patients."

This content was produced with the assistance of AI translation services.